CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) announced positive data from a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial evaluating ...

The FDA has accepted a Biologics License Application for imsidolimab to treat generalized pustular psoriasis, a rare inflammatory skin condition.

Accelerated review was enabled by the Commissioner’s National Priority Voucher Pilot Program, targeting high unmet need and ...

Argenx Se ( (ARGX)) has provided an update. On March 6, 2026, Argenx announced it will present extensive new data on VYVGART and its neurology pipeline at the American Academy of Neurology Annual ...

Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression-free survival and overall survival versus standard of care regimens83.3% of ...

Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical ...

NEW YORK, Feb. 24, 2026 /PRNewswire/ -- Today, EMED Technologies, a global leader in drug delivery and innovative infusion therapy devices announced that its subsidiary closed a successful $8 million ...

In 1996, a previously healthy 5-year-old girl presented to a local urgent care clinic with a 3-day history of fever and a progressive, generalized vesicular rash, diagnosed as varicella with a known ...

Dianthus Therapeutics (NASDAQ:DNTH) executives used a Biotech Summit 2026 discussion to outline upcoming clinical catalysts ...

Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and ...

Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net ...

Shares in Grifols SA fell more than 6% on Friday after the company declined to provide a 2026 revenue target alongside quarterly results, a move analysts warned c ...